Analysts Anticipate Immatics (NASDAQ:IMTX) to Announce $1.86 Earnings Per Share

Equities research analysts expect Immatics (NASDAQ:IMTX – Get Rating) to announce earnings per share of $1.86 for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Immatics’ earnings, with the lowest EPS estimate coming in at $1.65 and the highest estimate coming in at $2.07. Immatics posted earnings of ($0.41) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 553.7%. The business is scheduled to report its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Immatics will report full-year earnings of ($0.21) per share for the current financial year, with EPS estimates ranging from ($1.91) to $0.72. For the next year, analysts anticipate that the company will report earnings of ($1.77) per share, with EPS estimates ranging from ($2.32) to ($1.54). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Immatics.

A number of equities research analysts recently issued reports on IMTX shares. SVB Leerink lowered their target price on shares of Immatics from $32.00 to $25.00 and set an “outperform” rating for the company in a report on Thursday, March 24th. Zacks Investment Research downgraded shares of Immatics from a “buy” rating to a “hold” rating in a research note on Friday, April 8th.

Immatics stock opened at $8.56 on Friday. Immatics has a 1 year low of $6.48 and a 1 year high of $16.30. The firm has a 50 day moving average of $8.13. The stock has a market capitalization of $538.50 million, a P/E ratio of -5.10 and a beta of 0.39.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Woodline Partners LP raised its holdings in Immatics by 22.7% in the fourth quarter. Woodline Partners LP now owns 743,490 shares of the company’s stock valued at $9,993,000 after acquiring an additional 137,570 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Immatics in the 4th quarter valued at about $622,000. Sofinnova Investments Inc. lifted its position in shares of Immatics by 114.7% during the fourth quarter. Sofinnova Investments Inc. now owns 1,026,623 shares of the company’s stock worth $13,798,000 after purchasing an additional 548,407 shares during the last quarter. Marshall Wace LLP acquired a new position in Immatics in the fourth quarter worth about $41,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in Immatics during the fourth quarter valued at approximately $163,000. 35.71% of the stock is currently owned by institutional investors and hedge funds.

About Immatics (Get Rating)

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.

Read More